Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 3 months ago) | |
US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(5 months ago) | |
US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(5 months ago) | |
US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(10 days ago) | |
US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(10 days ago) | |
US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) |
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216176 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
US9572803 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
US8445018 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Jul, 2029
(5 years from now) |
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9265760 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9339499 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9433619 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9421200 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9610286 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9333201 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US10028946 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US10456393 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US10722511 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US10322120 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9326982 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
US9486451 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
US10092559 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
US9452163 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
US9132096 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
US9713611 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) |
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain in patients with hepatic impairment; Treatment of pain
Dosage: CAPSULE, EXTENDED RELEASE;ORAL